Multiple intracellular signaling pathways have been shown to regulate the hypertrophic growth of cardiomyocytes. Both necessary and sufficient roles have been described for the mitogen activated protein kinase 1 (MAPK) signaling pathway, specific protein kinase C (PKC) isoforms, and calcineurin. Here we investigate the interdependence between calcineurin, MAPK, and PKC isoforms in regulating cardiomyocyte hypertrophy using three separate approaches. Hearts from hypertrophic calcineurin transgenic mice were characterized for PKC and MAPK activation. Transgenic hearts demonstrated activation of c-Jun NH 2 -terminal kinase (JNK) and extracellular signal-regulated kinase (ERK1/2), but not p38 MAPK factors. Calcineurin transgenic hearts demonstrated increased activation of PKC␣, ␤ 1 , and , but not of ⑀, ␤ 2 , or . In a second approach, cultured cardiomyocytes were infected with a calcineurin adenovirus to induce hypertrophy and the effects of pharmacologic inhibitors or co-infection with a dominant negative adenovirus were examined. Calcineurin-mediated hypertrophy was prevented with PKC inhibitors, Ca 2؉ chelation, and attenuated with a dominant negative SEK-1 (MKK4) adenovirus, but inhibitors of ERK or p38 activation had no effect. In a third approach, we examined the activation of MAPK factors and PKC isoforms during the progression of load-induced hypertrophy in aortic banded rats with or without cyclosporine. We determined that inhibition of calcineurin activity with cyclosporine prevented PKC␣, , and JNK activation, but did not affect PKC⑀, ␤, , ERK1/2, or p38 activation. Collectively, these data indicate that calcineurin hypertrophic signaling is interconnected with PKC␣, , and JNK in the heart, while PKC⑀, ␤, , p38, and ERK1/2 are not involved in calcineurinmediated hypertrophy.
In response to multiple extrinsic or intrinsic stimuli the heart undergoes adaptive hypertrophy in an attempt to decrease wall tension and energy utilization. Cardiac hypertrophy is characterized by an increase in cell surface area of individual myocytes, enhanced sarcomeric organization, and the re-expression of specific fetal genes. While initially beneficial, prolonged cardiac hypertrophy eventually leads to decompensation, dilated cardiomyopathy, arrhythmia, fibrotic disease, sudden death, or overt failure (1) . Recent investigation has centered around identifying the intracellular signaling pathways that regulate the hypertrophic growth of cardiac myocytes so that novel pharmacologic therapies might be employed to prevent the long-term maladaptive effects of hypertrophy.
The hypertrophy of cardiomyocytes has been associated with alterations in intracellular signal transduction pathways, including Ras, the three main branches of the MAPK signaling cascade (ERKs, 1 JNKs, and p38s), PKC, and calcineurin. A large number of in vitro studies have identified important roles for the three branches of the MAPK signaling pathway in cardiomyocyte hypertrophy. Specifically, the importance of ERKs in cardiomyocyte hypertrophy has been proposed based on studies with the pharmacologic MEK1 inhibitor PD98059 or by transient transfection of cDNAs encoding activated or dominant negative MEK1 cDNAs (reviewed in Refs. 2 and 3). However, other studies have disputed the importance of ERK signaling in directing the hypertrophic program of cardiomyocytes in culture (4 -10) . A role for p38 and JNK signaling factors in hypertrophy has also been proposed based on pharmacologic inhibitors and overexpression of constitutively active or dominant negative MAPK factors (7) (8) (9) (10) (11) (12) (13) (14) . In contrast, two studies have reported that p38 inhibition was not sufficient to attenuate agonist-induced cardiomyocyte hypertrophy, suggesting more specialized roles for individual MAPK signaling factors (10, 15) . Consistent with this notion, a recent report demonstrated that ERKs were important at the onset of hypertrophic stimulation while p38 factors appeared to act later in response to agonist stimulation (16) .
Members of the protein kinase C (PKC) superfamily have also been shown to regulate hypertrophic growth of cardiac myocytes. Specific PKC isoforms are rapidly activated in the heart following agonist-induced G protein-coupled receptors activation (reviewed in Refs. 17 and 18) . Acute mechanical stretch of the left ventricle induces translocation of the PKC⑀ isoform, while chronic pressure overload activates PKC␣ and -⑀ isoforms in guinea pig heart (19, 20) . PKC␤ was also shown to be sufficient to mediate cardiac hypertrophy when overexpressed in the hearts of transgenic mice (21, 22) . Once activated, PKCs are thought to directly enhance hypertrophic gene expression by acting on transcription factors such as transcription enhancer factor-1, serum response factor, and spl (23, 24) . Lastly, the expression and activity of PKC␣ and -␤ isoforms are elevated in the failing human heart, supporting the notion that PKC isoforms regulate multiple responses in cardiomyocyte disease states (25, 26) .
More recently, an additional intracellular signaling pathway has been implicated in the control of cardiomyocyte hypertrophy through the calcium-dependent phosphatase calcineurin and the transcription factor nuclear factor of activated T-cells 3. Cardiac-specific expression of a constitutively active calcineurin cDNA in transgenic mice was shown to induce a 2-3-fold increase in heart size that rapidly progressed to overt failure (27) . Further evidence implicating this signaling pathway came from the observation that pharmacologic inhibition of calcineurin with cyclosporin A or FK506 was sufficient to attenuate hypertrophy of cultured neonatal cardiomyocytes induced by angiotensin II or PE (27) . This observation was extended in vivo whereby cyclosporin or FK506 were shown to block hypertrophy or dilation in three transgenic mouse models of cardiomyopathy (28) . Cyclosporine was also shown to significantly attenuate pressure overload hypertrophy induced by aortic constriction in the rat (28, 29) , mouse (30) , and G␣ q transgenic mice (31) , although similar studies reported no inhibitory effect with cyclosporine (32) (33) (34) (35) . Lastly, myocardial pressure overload was also shown to significantly induce cardiac calcineurin phosphatase activity (29) . However, the potential interplay between calcineurin and other hypertrophic signaling pathways is not known.
To this end, we investigated the interconnectivity between calcineurin and the other hypertrophy associated signaling pathways. Using three different approaches, calcineurin signaling was shown to be interconnected with PKC␣, PKC, and JNK in the induction and maintenance of cardiac hypertrophy.
EXPERIMENTAL PROCEDURES
Animals and Surgery-All procedures involving animals were approved by the institutional animal care and use committee. Calcineurin transgenic mice and their wild-type littermates were described earlier (27) . Pressure overload-induced hypertrophy in the rat heart was performed as described earlier (29) . Briefly, 200 -225 g Harlan SpragueDawley rats were anesthetized with isoflurane, a 1.0 silk ligature was tied around the abdominal aorta and a blunted 19-gauge needle below the celiac trunk, after which the needle was removed to create a defined constriction. Cyclosporine A (Novartis, Basel, Switzerland) treatment involved subcutaneous injections in the nape of the neck for 14 days starting 1 day prior to surgery. This treatment regimen with cyclosporine A was found to substantially reduce the morphologic, gravimetric, and histologic characteristics of load-induced hypertrophy (29) .
Primary Cardiomyocyte Cell Culture-Primary cultures of neonatal rat cardiomyocytes were obtained as described previously (36) . In brief, neonatal cardiac myocytes were obtained by enzymatic dissociation of 1-2 day old Harlan Sprague-Dawley rat neonates. The hearts were collected, atrial tissue was removed, and the ventricles were cut in four equal parts in a balanced salt solution prior to enzymatic digestion. The ventricular tissue was subjected to multiple rounds of enzymatic digestion using 0.05% pancreatin (Sigma) and 84 units/ml of collagenase (Worthington, Lakewood, NJ). Cells were collected by centrifugation at 800 rpm for 5 min at 4°C and resuspended in M199 media (Life Technologies, Inc.) supplemented with 15% fetal bovine serum, penicillin/streptomycin (100 units/ml), and L-glutamine (2 mmol/liter). Subsequently, the cells were differentially plated for 1 h on uncoated cell culture dishes to remove contaminating nonmyocytes. The cardiomyocytes (containing less than 10% nonmyocytes) were then plated on gelatinized cell culture dishes and cultured the following day in serumfree M199 media containing serum-free media supplement (Nutridoma; Roche Molecular Biochemicals), 100 units/ml penicillin/streptomycin, and 2 mmol/liter L-glutamine. Cardiomyocytes were maintained in serum-free M199 media for 48 h before adenoviral infections and/or treatments.
Replication-deficient Adenovirus Infections-The construction, characterization, and procedures of cardiomyocyte infections with replication-deficient adenovirus expressing a constitutively activated form of calcineurin (AdCnA) and ␤-galactosidase (Ad␤gal) was recently described in detail (37) . All recombinant adenoviral vectors were plaque purified, expanded, and titered by detection of formation of visible plaques in a HEK293 monolayer of cells using the agarose gel overlay method. Typical experiments involved infection of neonatal rat cardiomyocytes at a multiplicity of infection of 100 plaque forming units for 2 h at 37°C in a humidified, 6% CO 2 incubator. Subsequently, the cells were cultured in serum-free M199 media for an additional 24 h prior to treatments. Under these conditions approximately 98% of the cells stained ␤-galactosidase positive following Ad␤gal infection.
Immunocytochemistry-Cardiomyocytes were prepared for immunocytochemistry as described previously (27) . A monoclonal antiserum to sarcomeric ␣-actinin (EA-53) and a polyclonal antibody to ANF were purchased from Sigma and Peninsula Laboratories (San Carlos, CA) and used at a dilution of 1:800 and 1:200, respectively. Secondary antibodies included anti-mouse tetramethylrhodamine B isothiocyanate-conjugated antibody (Sigma) and anti-rabbit fluorescein isothiocyanate-conjugated antibody (Sigma) each at a dilution of 1:400. Quantitation of cardiomyocyte cell surface area was performed on ␣-actininstained cardiomyocytes using confocal laser microscopy and NIH Image software on a Sun system workstation. At least 100 cardiomyocytes in 15-25 fields at ϫ 400 magnification were examined. For quantitation of ANF positive cardiomyocytes, ANF and ␣-actinin positive cells in at least 10 fields were quantified (typically 40 cells in each field at ϫ 200).
Measurement of Calcium Transients-For calcium transient measurements, primary rat neonatal cardiomyocytes were loaded with Indo-1 PE3 (TEFLABS) at 3 M for 20 min and washed in serum-free M199 media and subsequently measured for 405/490 nM ratio emission after excitation at 355 nm at 30°C in a incubation chamber on the stage of an inverted Nikon epiflourescence microscope at ϫ 200 using a PTI (Photon Technology Inc.) Delta Scan dual beam spectrophotofluorometer instrument, similar to a previous description (38) . Cardiomyocytes were paced at 0.5 Hz with a Grass S9 stimulator and the data were collected and analyzed with the Felix software package (PTI). Data are presented as mean Ϯ S.E. of 15-20 cells each from two independent experiments.
Western Blot Analysis-Protein extracts were generated from cultured cardiomyocytes using extraction buffer (20 mM NaPO 4 , 150 mM NaCl, 2 mM MgCl 2 , 0.1% Nonidet P-40, 10% glycerol, 10 mM sodium fluoride, 0.1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 M phenylasine oxide, 10 nM okadaic acid, 1 mM dithiothreitol, 10 g/ml leupeptin, 10 g/ml aprotinin, 10 g/ml pepstatin, 10 g/ml tosyl-L-phenylalanine chloromethyl ketone, and 10 g/ml N ␣ -tosyl-Llysine chloromethyl ketone). Samples were subjected to SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane (Amersham Pharmacia Biotech), and blocked in 7% milk. Primary antibodies were incubated overnight at room temperature in 3% milk. Secondary antibodies IgG (alkaline phosphatase) were incubated for 1 h at room temperature in 3% milk. Chemiluminescent detection was illuminated with Vistra ECF (Amersham Pharmacia Biotech) and scanned utilizing a Storm 860 (Molecular Dynamics, Sunnyvale, CA). Antibodies used included: phospho-MEK1/2, MEK1/2, phospho-ERK1/2, phospho-MKK3/6, MKK3/6, phospho-p38, p38, phospho-MKK4, MKK4, phospho-JNK, and JNK (New England Biolabs, Beverly, MA), PKC␣, PKC␤1, PKC␤2, PKC, PKC⑀, PKC (Santa Cruz), and ERK1/2 (Transduction Laboratories). Purified PKC␣ and ⑀ protein (Upstate Biotechnology) was used to generate a standard curve Western blot immunoreactivity to allow quantitative assessment of total cardiac PKC␣ and ⑀ protein levels in cardiac protein extracts.
Immune Complex Kinase Assays-Immune complex kinase assays for ERK and JNK were performed as described previously (10) . Hearts from 2 calcineurin transgenic mice or 2 wild-type controls were pulverized under liquid nitrogen and lysis buffer was added followed by brief sonication. Soluble protein extracts (equal amounts of protein) were incubated with antibodies to ERK-1 and ERK-2, or JNK1 (Santa Cruz) for 3 h. Complexes were collected with protein G-Sepharose beads and washed 6 times in lysis buffer and 3 times in assay buffer. Substrates for the kinases were glutathione S-transferase (GST)-c-Jun (amino acids 1-135) for JNK activity and myelin basic protein for ERK1/2. The reaction was started by the addition of 100 M [␥- 32 P]ATP and incu-bated at 30°C for 20 min. Reactions were then stopped with SDS sample buffer and subjected to SDS-polyacrylamide gel electrophoresis and autoradiography. Bands corresponding to the substrate were cut out of the gel and incorporation of 32 P was determined by scintillation counting.
PKC Translocation Assay Tissue Preparation-Left ventricular free wall samples from both mouse and rat hearts were frozen in liquid nitrogen and stored at Ϫ70°C. Heart samples were homogenized in 25 mM Tris-Cl, pH 7.5, 4 mM EGTA, 2 mM EDTA, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and 1 g/ml leupeptin, and incubated for 30 min on ice. Samples were then spun at 100,000 ϫ g for 30 min at 4°C. The supernatant product was saved as the cytosolic fraction while the remaining pellet was resuspended in homogenization buffer with the addition of 1% Triton X-100. The sample was then re-homogenized and ice incubated for 30 min. All samples were spun again at 100,000 ϫ g for 30 min at 4°C, and the remaining supernatant was saved as the particulate fraction. Protein concentration was quantified using the Bradford method (Bio-Rad).
PKC Activity Assay-Total PKC activity was determined from both cytosolic and particulate protein fractions combined. This radioactive enzymatic assay (SignaTECT PKC assay system, Promega) involved a PKC-catalyzed transfer of 32 P from [␥-32 P]ATP. In brief, all mouse left ventricular samples were homogenized in extraction buffer (25 mM Tris-Cl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 0.05% Trition X-100, 10 mM ␤-mercaptoethanol, 1 g/ml leupeptin, 1 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride) and spun at 14,000 ϫ g for 5 min at 4°C. The recovered supernatant was passed over a DEAE cellulose column to purify PKC proteins. PKC activity assays were performed in the presence of phospholipids (phosphatidylserine) and a PKC biotinylated peptide substrate, while a duplicate reaction was carried out in the absence of phospholipids (control reaction). All reactions were incubated at 30°C for 5 min, and 32 P incorporation was measured by transferring the completed reactions onto S-adenosylmethionine membranes (Promega). Results were quantified utilizing a PhosphorImager (Molecular Dynamics).
Statistical Analysis-Data are expressed as mean (ϮS.E.). Differences between experimental groups were evaluated for statistical significance using Student's t test for unpaired data or one-way ANOVA followed by Bonferroni's post-test. p values Ͻ 0.05 were considered to be statistically significant.
RESULTS

Calcineurin Activates JNK (p54) and PKC Isoforms in Vivo-
Transgene-mediated expression of an activated calcineurin protein in the heart produces a dramatic hypertrophy response beginning at days 8 -10 postnatal and culminating in lethal hypertrophic and dilated cardiomyopathy 8 -12 weeks thereafter (27) . The intracellular mechanisms whereby activated calcineurin leads to cardiac hypertrophy is uncertain, although activation of the transcription factor nuclear factor of activated T-cells 3 is thought to mediate part of calcineurin's effects (27) . However, we reasoned that calcineurin-mediated hypertrophy was likely acting in concert with other reactive signaling pathways to orchestrate a balanced hypertrophic response. To investigate this notion, we performed an extensive Western blot survey of known hypertrophy producing signaling factors from protein extracts generated from calcineurin transgenic hearts. The activation state of the three terminal MAPK branches was investigated at days 14 and 25 using phosphorylation-specific antibodies. No activation of the p38 branch was observed in calcineurin TG hearts, while a significant activation of JNK (p54) was observed (Fig. 1A) . We also observed a subtle, but reproducible increase in ERK1/2 phosphorylation state in calcineurin TG hearts (Fig. 1A) . These data were confirmed by immune kinase activity assays, which demonstrated a significant activation of JNK (1.7-fold)(p Ͻ 0.05), and a trend toward activation of ERK1/2 (p ϭ 0.07) in calcineurin TG hearts (Fig.  1B) .
We also investigated the possible involvement of PKC isoforms in the genesis of cardiac hypertrophy in calcineurin transgenic mice. Using a PKC-specific phosphorylation assay (39), total PKC activity was found to be elevated in calcineurin transgenic hearts compared with littermate non-transgenic hearts at day 4, 8, 14, and 25 ( Fig. 2A) . Increased kinase activity was most apparent at day 14, as a 2.4-fold increase was observed compared with non-transgenic littermates of the same age. These data prompted a more detailed assessment of the activation state of several PKC isoforms by quantifying PKC translocation into the particulate fraction in protein extracts from calcineurin TG hearts. Absolute protein levels were also quantified in the cytosolic protein fraction. Western blot quantitation demonstrated a significant increase in cytosolic PKC⑀ (2.2-fold), and a smaller increase in cytosolic PKC␣, ␤1, , and (Fig. 2, B and C) . In contrast, PKC␤2 cytosolic protein levels were dramatically reduced. Interestingly, PKC␣, ␤1, and were each significantly translocated to the particulate fraction, inferring activation (relative to cytosolic content) (Fig. 2, B  and C) . Also of note, PKC translocation to the particulate fraction was reduced (Fig. 2, B and C) . These data suggest an association between calcineurin-mediated hypertrophy and the translocation of PKC␣, ␤1, and .
In Vitro Assessment of Calcineurin-mediated Hypertrophy using Adenoviral-mediated Gene Transfer-To further investigate the interconnectivity between calcineurin and other intracellular signaling factors in mediating hypertrophy, an in vitro system using cultured neonatal rat cardiomyocytes was employed. A replication-deficient adenovirus expressing a consti-FIG. 1. Activation profile of JNK, ERK1/2, and p38 MAPK in the hearts of calcineurin transgenic mice. A, Western blot analysis of phosphorylated JNK (p54), ERK1/2, and p38 from hearts of calcineurin transgenic and non-transgenic littermate mice at 14 and 25 days. The amounts of total JNK, ERK1/2, and p38 protein did not vary as assayed with protein-specific antibodies. Asterisks indicate increased phosphorylated JNK (p54) levels and the subtle, yet consistent increase in ERK1/2 phosphorylation in calcineurin transgenic hearts at days 14 and 25 (n ϭ 2 separate hearts each). B, immune complex kinase assay for JNK and ERK1/2 activity in calcineurin TG hearts (*, p Ͻ 0.05). A significant increase in JNK activity was observed while a trend toward increased ERK1/2 kinase activity was noted (n ϭ 2 hearts each).
tutively activated form of calcineurin (AdCnA) was used to induce cardiomyocyte hypertrophy in vitro. AdCnA infection significantly increased cardiomyocyte surface area, sarcomeric organization, and ANF expression (37) , consistent with the effects of activated calcineurin in transgenic mice (27) . Recombinant adenoviral infection (with calcineurin or a control ␤-galactosidase encoding virus) routinely produced 98% infection of cardiomyocytes in culture.
In addition to inducing phenotypic hypertrophy, we noted that AdCnA infection noticeably augmented cardiomyocyte beating, suggesting enhanced inotropy (data not shown). This observation prompted us to quantify the calcium transients of single AdCnA infected, Indo-1 loaded cardiomyocytes. We determined that AdCnA infection (24 h) induced a significant increase in the amplitude of the calcium transient. Ad␤gal-infected myocytes had a average Indo-1 405/490 ratio of 0.56 Ϯ 0.05 while AdCnA infected myocytes had a value of 0.82 Ϯ 0.05 (Ϯ S.E., p Ͻ 0.05). These data indicate that calcineurin-mediated hypertrophy is associated with an increase in the calcium transient, similar to agonist-induced hypertrophy (40 -44 (Fig. 3A) . In contrast, cultured cardiomyocytes infected with AdCnA and treated with either an inhibitor of the p38 MAPK signaling pathway (SB202190, 20 M) or the MEK-1/ERK MAPK pathway (PD098059, 10 or 25 M) did not demonstrate inhibited cell growth (2098 Ϯ 114 M and 2007 Ϯ 229 m 2 , respectively). These data indicate that PKC activation is necessary for cardiac hypertrophy in response to calcineurin signaling in vitro. These data also indicate that ERK and p38 MAPK are not critical in calcineurin-mediated hypertrophy.
AdCnA infection was shown to increase the calcium transient, suggesting two additional mechanisms whereby calcineurin might induce hypertrophy. Increases in the calcium transient are thought to promote cardiac hypertrophy by either increasing the intensity of contraction itself or by activating calcium-dependent signaling pathways (43, 45) . To distinguish between these two mechanisms, AdCnA-infected cardiomyocyte cultures were treated with 7 mM BDM to inhibit actomyosin sarcomeric cross-bridge formation, which abolished spontaneous contractions in cardiomyocyte cultures. Even though BDM prevented cardiomyocytes from beating, AdCnA still induced a similar degree of cardiac hypertrophy (cell size 2024 Ϯ 162 m 2 ) (Fig. 3A) . These data indicate that AdCnA-induced hypertrophy is not dependent on increased beating frequency or intensity.
To further examine the mechanism whereby calcium might promote cardiac hypertrophy in AdCnA-infected myocytes, intra-and extracellular Ca 2ϩ levels were antagonized pharmacologically. Intracellular or extracellular Ca 2ϩ chelation by BAPTA-AM 2.5 M or EGTA 2 mM, respectively, inhibited cardiomyocyte hypertrophy mediated by AdCnA infection (cell size 1107 Ϯ 47 m 2 and 1512 Ϯ 81 m 2 , respectively) (Fig. 3A) . This inhibition of hypertrophy was similar to that seen with cyclosporine (data not shown). The observed inhibition of hypertrophy with BAPTA-AM or EGTA indicates that the availability of Ca 2ϩ is absolutely necessary for AdCnA to elicit a full increase in cell size. These data suggest that calcineurin-mediated hypertrophy depends on additional calcium-sensitive signaling factors, such as PKC (as shown above).
To confirm the effects of pharmacologic inhibitors in blocking AdCnA-mediated hypertrophy, expression of the hypertrophic marker gene ANF was characterized. AdCnA infection significantly increased the percentage of cardiomyocytes expressing ANF as compared with Ad␤gal-infected cells (66 Ϯ 3 and 10 Ϯ 2%, respectively; Fig. 3B ). PKC inhibition with chelerythrine or PMA significantly attenuated the percentage of AdCnA-infected cells that expressed ANF (38 Ϯ 3 and 21 Ϯ 3%, respectively) (p Ͻ 0.05 versus AdCnA alone). p38 and ERK inhibition did not influence ANF expression in AdCnA-infected cultures (56 Ϯ 3 and 59 Ϯ 3%, respectively), nor did BDM-mediated inhibition of contraction (61 Ϯ 4%) (Fig. 3B) . However, both BAPTA-AM and EGTA significantly impaired ANF expression in AdCnA-infected cultures (11 Ϯ 2 and 10 Ϯ 1%, respectively) (Fig. 3B) . These results are consistent with the inhibition of two-dimensional surface area mediated by the same pharmacologic inhibitors.
We also characterized the morphology, sarcomeric organization, and intensity of ANF protein expression of AdCnA-infected myocytes treated with each of the pharmacologic inhibitors. We observed that the relative intensity of ANF expression within individual myocytes was significantly attenuated by PKC inhibitors, BAPTA-AM, and EGTA (Fig. 4, J and L, and data not shown). However, inhibition of beating (BDM), p38, or ERK1/2 signaling did not diminish the intensity of ANF expression (Fig. 4, F and H, and data not shown) . The observed pattern of perinuclear ANF immunocytochemical staining is consistent with previous reports (11, 12) . ANF-labeled cells were also co-labeled with ␣-actinin antibody to allow visualization of cellular morphology and sarcomeric organization (Fig. 4,  A, C, E, G, I, and K) . Inspection of ␣-actinin-labeled cardiomyocytes demonstrated that AdCnA infection induced a hypertrophic phenotype characterized by increased cell surface area and enhanced sarcomeric organization (compared with Ad␤gal-infected myocytes) (Fig. 4, A and C) . PKC inhibition (Fig. 4K ) or calcium antagonism (Fig. 4I) blocked AdCnA-induced hypertrophic morphology. However, inhibition of beating, p38, or ERK signaling did not significantly affect hypertrophic morphology (Fig. 4, G and E, and data not shown) . Collectively, these data demonstrate that calcineurin-mediated hypertrophy, characterized by increased surface area, hypertrophic morphology, and ANF expression, is a unique program that is independent of ERK and p38, but dependent on PKC activity and calcium.
Inhibition of JNK Signaling Attenuates Calcineurin-mediated Hypertrophy in Vitro-Characterization of MAPK activation in calcineurin transgenic hearts revealed an increase in JNK phosphorylation (Fig. 1A) . However, we were not able to ascertain the importance of JNK signaling as a co-regulator of calcineurin-induced hypertrophy in vitro, given the lack of specific inhibitors. To overcome this limitation, we utilized a dominant negative SEK-1 expressing adenovirus, AdSEK-1dn (10). SEK-1 (MKK4) regulates JNK activation and adenoviral-mediated overexpression of a dominant negative mutant was previously shown to attenuate endothelin-1-induced cardiomyocyte hypertrophy in vitro (10) , and pressure overload hypertrophy in vivo (14) . To determine the importance of JNK activation in the calcineurin-mediated hypertrophic response, we co-infected cultured cardiomyocytes with AdCnA and Ad-SEK-1dn. Ad␤gal infection by itself did not induce phenotypic hypertrophy or significant ANF expression (Fig. 5, A and B) . As a positive control, Ad␤gal infection was permissive to the in- duction of hypertrophy in response to PE (Fig. 5, C and D) . An additional control demonstrated that co-infection with Ad␤gal and AdCnA induced a significant hypertrophic response (Fig. 5,  E and F) . However, AdSEK-1dn attenuated AdCnA-induced phenotypic hypertrophy and ANF protein expression (Fig. 5, G  and H) .
To quantify the effect of JNK inhibition on AdCnA-induced hypertrophy, cell surface areas were measured (Fig. 6A ). The data demonstrate that co-infection with Ad␤gal and AdCnA induced an approximate 86% increase in the two-dimensional area compared with Ad␤gal infection alone. In contrast, Ad-SEK-1dn co-infection with AdCnA attenuated this increase by approximately 70% (Fig. 6A) . However, AdSEK-1dn did not completely block AdCnA-mediated hypertrophy, as evidenced by a significant increase in two-dimensional area compared with Ad␤gal alone. As an additional control, we also observed that AdSEK-1 infection lead to an approximated 50% inhibition of PE-mediated hypertrophy, consistent with its ability to attenuate endothelin-1-induced hypertrophy described previously (10) (Fig. 6A) . To further quantify the effect of JNK inhibition on calcineurin-mediated hypertrophy, ANF expression was scored in cardiomyocytes (Fig. 6B) . Consistent with the measurements of cell surface area, AdSEK-1dn co-infection attenuated the percentage of cardiomyocytes expressing ANF protein. Collectively, these data indicate that JNK activation is an important component of the calcineurin-induced hypertrophy response.
Inhibition of Calcineurin in Vivo Blocks JNK, PKC␣, and PKC Activation during Pressure Overload Hypertrophy-To
further explore interconnections between MAPK signaling pathways and calcineurin in vivo, the activation states of ERK1/2, p38, and JNK were assessed in the left ventricles of abdominal aortic-banded rats treated with cyclosporine A for 14 days (Fig. 7) . This approach was taken so that interconnectivity between calcineurin and MAPK factors could be assessed in a physiologic model of hypertrophy, without overexpressing calcineurin. Cardiac pressure overload due to abdominal aortic banding induced a 30 -40% increase in heart size over 14 days compared with sham operated rats and was characterized by a nearly 3-fold increase in calcineurin phosphatase activity (29) . Treatment of aortic-banded rats with cyclosporine over these 14 days significantly attenuated cardiac hypertrophy and calcineurin activity in a dose-dependent manner (29) . For purposes of this study, we reasoned that inhibition of calcineurin might affect the activation of MAPK factors or PKC isoforms in response to load-induced hypertrophy.
The data demonstrate that inhibition of calcineurin with cyclosporine did not prevent ERK or p38 activation after 14 days of load-induced hypertrophy (Fig. 7) . However, cyclosporine treatment for 14 days blocked JNK (p54) activation in aortic-banded rats (Fig. 7) . Protein levels for each factor did not vary suggesting that the differences in phospho-protein detection accurately reflects activation. These results suggest that calcineurin may function upstream of JNK during the loadinduced response, but that calcineurin likely functions in parallel or downstream of ERK1/2 and p38 pathways. These data are consistent with the observed interconnectivity between calcineurin and JNK in vitro (Figs. 5 and 6) , and the lack of significant interconnectivity between calcineurin and p38 and ERK1/2.
To explore the interconnectivity between calcineurin and PKC isoforms, Western blots were performed to quantify PKC translocation in the left ventricle in response to load induced hypertrophy from animals that were treated with cyclosporine or vehicle. We determined that pressure overload hypertrophy in the rat is associated with increased cytosolic levels of PKC␣, ␤ 1 , ⑀, , , but not ␤ 2 (Fig. 8, A and B) . Interestingly, only PKC␣ and showed a relative increase in the particulate fraction in response to load-induced hypertrophy. More striking, cyclosporine administration over 14 days to aortic banded rats (which attenuates their hypertrophy) blocked PKC␣ and translocation to the particulate fraction, suggesting that inhibition of calcineurin blocked activation of these two PKC isoforms. Cyclosporine did not block the increase in cytosolic PKC␤ 1 , ⑀, ␤ 2 , or , nor did it block their relative translocation to the particulate fraction (Fig. 8, A and B) . To more carefully quantify PKC levels and translocation, PKC␣ and ⑀ protein standards were obtained and Western blotted together with heart protein fractions (n ϭ 3 each) to generate a standard curve of absolute protein concentration (Fig. 8, C and D) . In 100 g of loaded protein sample, approximately 6.7 and 6.0 ng of PKC␣ protein was present in the particulate and cytosolic fraction of sham hearts, respectively. These values increased to 16.5 and 15.6 in the hearts of aortic-banded rats (particulate and cytosolic, respectively). Cyclosporine treatment significantly reduced PKC␣ concentration in both protein fraction (Fig. 8E) . PKC⑀ also increased in response to aortic banding (from 2.4 ng, particulate; 1.3 ng, cytosolic; to 5.8 ng, particulate; 3.1 ng, cytosolic). However, in contrast to PKC␣, PKC⑀ levels and translocation were not reduced by cyclosporine (Fig. 8F) . Collectively, these data suggest that calcineurin is involved in PKC␣ and activation in response to load-induced hypertrophy. These data also suggest that attenuation of hypertrophy with cyclosporine is multifactorial, such that JNK, PKC␣, and PKC are also inhibited.
DISCUSSION
Numerous studies have implicated roles for a wide range of intracellular signaling factors in cardiac hypertrophy. However, very little is known of the interconnectivity or hierarchies among multiple signaling pathways in the heart. Here we utilized three different approaches to investigate the interconnectivity between calcineurin hypertrophic signaling and MAPK and PKC factors. 1) Calcineurin transgenic hearts were characterized for the activation state of different signaling factors in vivo. 2) Adenoviral-mediated gene transfer of an activated calcineurin cDNA was performed in cultured cardiomyocytes and the effects of pharmacologic and dominant negative inhibitors were investigated. 3) A physiologic model of pressure overload hypertrophy was employed to determine if inhibition of endogenous calcineurin affects the activation of other signaling factors in vivo. All three approaches implicated cross-talk between calcineurin, PKC, and JNK. FIG. 7 . Inhibition of calcineurin with cyclosporine prevents activation of JNK (p54) during load induced hypertrophy in vivo. Western blots from left ventricular protein extracts using phospho-specific antibodies revealed an activation of ERK1/2, p38, and JNK (p54) from pressure loaded rat hearts (14 days after banding). Cyclosporine A treatment for 14 days during the banding procedure did not affect ERK1/2 and p38 activation, but JNK (p54) activation was inhibited. Total protein levels did not vary. Extracts were generated from two separate hearts for each condition FIG. 8. Inhibition of calcineurin with cyclosporine blocks PKC␣ and PKC activation during load induced hypertrophy. A, cytosol or particulate protein fractions were generated from the hearts of sham rats, aortic-banded rats, or banded rats treated with cyclosporine and Western blotted to quantify PKC isoform distribution (n ϭ 3 separate hearts each). B, histogram of the Western blots shown in A demonstrating increased PKC␣ and PKC protein content in the particulate and cytosolic of aortic band rat hearts, which was inhibited with cyclosporine. In contrast, banding induced an increase in total PKC␤1 and PKC⑀ content, which was not influenced by cyclosporine. C and D, PKC␣ and ⑀ bacterially produced protein was used to generate a standard curve of quantity versus PhosphorImager light units from scanned Western blots. E and F, these standards were used to quantify the absolute amount of PKC␣ and ⑀ in both the particulate and soluble protein fractions from the indicated treatment groups (n ϭ 3 each). The data are consistent with the non-standardized Western blots shown in A.
Interconnection between Calcineurin and PKC in Cardiac Hypertrophy-Calcineurin transgenic hearts were characterized by a significant activation of PKC␣, PKC, and PKC␤1 isoforms as detected by translocation to the membrane or particulate subcellular fraction. In cultured cardiomyocytes, calcineurin mediated hypertrophy by adenoviral gene transfer was blocked by PKC inhibition using either chelerythrine or PMA-induced down-regulation. Lastly, cyclosporine treatment of aortic-banded rats blocked PKC␣ and PKC activation in the heart in vivo. These data suggest that calcineurin-directed hypertrophy requires PKC activation, suggesting at least one interconnection between two signaling cascades in the heart. A potential interconnection between PKC and calcineurin has already been suggested in other cell types. Numerous studies in immune cells have shown that calcium inophores (calcineurin activation) and PKC agonists synergistically activate inducible promoters or immune response genes (reviewed in Ref. 46 ). PKC and calcineurin were shown to synergistically activate IB kinase activity in T cells, resulting in NF-B activation (47) , and nPKC isoforms were shown to be activated by calcineurin during thymocyte apoptosis (48) . It is also interesting to note that PKC and calcineurin share a common intracellular docking protein, AKAP79, which may be involved in coordinating reactive responses (49) . However, the mechanisms whereby a kinase (PKC) and a phosphatase (calcineurin) might synergize to promote reactive signaling in either T-cells or cardiac myocytes is unknown. One possible hypothesis is that each pathway may counterbalance the net effect of the other pathway so that desensitization is avoided. Consequently, maintaining a balance between net phosphorylation and dephosphorylation might allow for enhanced cycling of multiple reactive signaling effectors.
Interconnection between Calcineurin and MAPK in Cardiac Hypertrophy-We also analyzed the interconnectivity between calcineurin and MAPK signaling factors. Calcineurin transgenic hearts demonstrate activation of JNK (p54), mild ERK1/2 activation, but not of p38. In fact, careful inspection of multiple time points suggests that p38 phosphorylation might be downregulated in calcineurin TG hearts (Fig. 1A , and data not shown). In vitro, a dominant negative SEK-1 adenovirus attenuated AdCnA-induced hypertrophy in cultured cardiomyocytes, while p38 and ERK1/2 inhibition did not effect AdCnA-induced hypertrophy. Lastly, cyclosporine treatment of aortic-banded rats blocked JNK (p54) activation in the heart, while p38 and ERK1/2 remain in an enhanced phosphorylation state.
The observation that cyclosporine significantly attenuates load-induced hypertrophy (29) , despite p38 and ERK1/2 activation, suggests that these two signaling pathways are not critical for maintaining load-induced hypertrophy in the absence of additional signaling pathways. However, these data might also simply suggest that calcineurin is parallel to ERK and p38 signaling pathways in programming cardiac hypertrophy. A number of in vitro studies have implicated an important role for either p38 or ERK signaling in the hypertrophy of cultured cardiomyocytes (reviewed in Refs. 2 and 3). Despite these positive reports, a nearly equal number of in vitro studies have disputed the importance of either ERKs or p38 MAPK factors in mediating cultured cardiomyocyte hypertrophy (4 -15) . For example, adenoviral-mediated infection of an activated MKK6 factor (activates p38) or transfection of the MKK6 cDNA was reported to induce cardiomyocyte hypertrophy in vitro, suggesting a sufficient role for p38 in hypertrophy (8, 11 ). Yet, pacing induced cardiomyocyte hypertrophy was shown to be associated with a down-regulation of p38 activity, despite progressive hypertrophy (15) . This later observation is interesting since pacing might be predicted to activate calcineurin through enhanced inotropy.
A number of recent studies have shown that the stressactivated protein kinases (SAPKs or JNKs) are critical regulators of cardiac hypertrophy in vitro and in vivo. Choukroun et al. (14) demonstrated that dominant negative inhibition of JNK in vivo attenuated load-induced hypertrophy in aorticbanded rats. JNKs have also been reported to be activated by pressure overload hypertrophy in aortic-banded rats and JNK activation was shown in the remote myocardium of infected rat hearts (14, 50) .
Calcineurin, PKC, and JNK as an Interconnected Regulatory Network-Recently, calcineurin was shown to synergize with PKC to activate JNK activity and expression of the interleukin-2 promoter (51). In T-cells, cyclosporine was shown to inhibit JNK activation and interleukin-2 promoter activity (52) . These reports are interesting considering the relationship that we have identified between calcineurin, PKC, and JNK in cardiomyocytes. It is possible that a conserved interconnected regulatory circuit exists between calcineurin, PKC, and JNK in multiple cell types. Indeed, PKC may even regulate calcineurin activity through phosphorylation of serine 411 within the calmodulin-binding domain (53, 54) . This paradigm would suggest that targeted inhibition of one or more of these three components would diminish the entire reactive signaling response. We have previously shown that inhibition of calcineurin with cyclosporine or FK506 attenuates cardiac hypertrophy in vivo (28, 29) . The observation that cyclosporine also effects PKC and JNK activation explains how direct inhibition of a single factor, calcineurin, attenuates the entire hypertrophic response in vivo. Consistent with this notion, direct inhibition of either JNK or PKC also attenuates the hypertrophic response (10, 14, 55) .
In this report, we show that cyclosporine inhibits PKC␣ and PKC activation in pressure overloaded hearts (Fig. 8, A and  B) . It is unlikely that cyclosporine directly inhibits PKC␣ or PKC in the heart given a lack of precedence in other cell types, although this interpretation cannot be ruled out. However, the simplest interpretation is that cyclosporine leads to calcineurin inhibition which ultimately effects PKC␣ and activation. Taken together, these data suggest that an interconnected network between calcineurin, PKC, and JNK are of critical importance in cardiac hypertrophy. This paradigm would more fully explain why targeted inhibition of any one of these three signaling pathways diminishes the entire hypertrophic response.
Potential Cross-regulation between Calcineurin and Calcium Handling-Calcineurin is activated by increased intracellular calcium concentration through association with calmodulin. The catalytic subunit of calcineurin is also regulated by the EF-hand calcium-binding protein calcineurin B (reviewed in Ref. 56 ). In cardiomyocytes, we have shown that adenoviral gene transfer of an activated calcineurin cDNA leads to an increase in the calcium transient. We have also determined that cardiac myocytes derived from adult calcineurin transgenic hearts have a significant increase in the calcium transient. 2 Taken together, these data suggest a working hypothesis whereby calcineurin may function as a calcium thermostat. Indeed, calcineurin in yeast regulates the activity of the calcium pump, and calcineurin in mammalian cells is associated with the inositol 1,4,5-trisphosphate receptor and potentially regulates the release of reactive calcium (57, 58) . However, the direct mechanisms whereby calcineurin-directed dephosphorylation would augment calcium release or affect subcellular pools of reactive calcium in a cardiomyocyte is not known.
Model of Calcineurin-induced Cardiac Hypertrophy-This study begins to examine the potential interconnections between multiple intracellular mediators and the orchestration of the hypertrophic response. To date, no study has shown a direct mechanism whereby calcineurin-mediated dephosphorylation might lead to the activation of another intracellular signaling kinase. Given this limitation, a number of scenarios might account for the interconnective signaling between calcineurin, PKC, and JNK in the heart. It is formally possible that calcineurin directly dephosphorylates a PKC or JNK regulatory protein, permitting or enhancing their activation. Indeed, PKC and calcineurin are co-localized to the common docking protein AKAP79, where direct communication may occur. However, it is also possible that calcineurin activation simply leads to the general promotion of the hypertrophic phenotype which indirectly leads to PKC and JNK activation. Calcineurin activation may set in motion a program of hypertrophy such that reinforcing signaling networks are activated which eventually lead to JNK and PKC activation. For example, initiation of hypertrophy is associated with autocrine release of angiotensin II and endothelin-1 which leads to re-entrant signaling through the G-protein-coupled receptors, which in turn activates additional reactive signaling pathways.
Lastly, calcineurin activation might also indirectly lead to PKC and JNK activation through effects on intracellular calcium handling or by augmenting a reactive pool of intracellular calcium. Future studies will be directed at identifying targets for calcineurin dephosphorylation that might lead to direct activation of PKC or MAPK factors.
